(PDF) Add-On Therapy With Montelukast or Formoterol in

Add-On Therapy With Montelukast or Formoterol in Patients With the Glycine-16 Β2-Receptor Genotype

British Journal of Clinical Pharmacology - United Kingdom

doi 10.1046/j.1365-2125.2003.01899.x

Full Text

Abstract

Available in full text

Categories

Date

July 9, 2003

Authors

Catherine M. Jackson

Brian J. Lipworth

Publisher

Wiley

Related search

The Arginine-16 Β2-Adrenoceptor Polymorphism Predisposes to Bronchoprotective Subsensitivity in Patients Treated With Formoterol and Salmeterol

British Journal of Clinical Pharmacology

English

Topiramate Add-On Therapy for Adult Patients With Refractory Epilepsy in Japan

Epilepsy and Seizure

English

Magnitude of a Conformational Change in the Glycine Receptor Β1-Β2 Loop Is Correlated With Agonist Efficacy

Journal of Biological Chemistry

Molecular Biology

English

Fludarabine Add-On Therapy in Interferon-Beta-Treated Patients With Multiple Sclerosis Experiencing Breakthrough Disease

Therapeutic Advances in Neurological Disorders

English

Autoantibodies Activating the Β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma

Frontiers in Immunology

English

The Effect of Denervation and Treatment With the Β2-Agonist, Formoterol, on the Masseter Muscles of Growing Sprague Dawley Rats

International Journal of Dentistry and Oral Health

English

Erratum To: Evaluation of Add-On Therapy of Sitagliptin in Japanese Patients With Type 2 Diabetes Under Insulin Therapy

Diabetology International

Internal Medicine

English

Economic Impact of Asthma Therapy With Fluticasone Propionate, Montelukast, or Zafirlukast in a Managed Care Population

Pharmacotherapy

English

Β2-Adrenergic Receptor-Mediated Histamine H1 Receptor Down-Regulation: Another Possible Advantage of Β2 Agonists in Asthmatic Therapy

Journal of Pharmacological Sciences

Molecular Medicine

English